(UroToday.com) The game changing session of the European Association of Urology (EAU)’s 2021 annual meeting included a presentation by Dr. Michael Hofman from the Peter MacCallum Cancer Centre discussing the phase 2 trial of 177Lu-PSMA-617, TheraP, as well as important contrasts/differences between TheraP and VISION. TheraP was an ANZUP/PCFA sponsored trial that began in 2016 and represents a world-first study, being a phase III randomized controlled trial of a direct targeted radioligand.